Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers
Authors
Keywords
-
Journal
PROSTATE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-10-26
DOI
10.1002/pros.24638
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
- (2022) Alison C Tree et al. LANCET ONCOLOGY
- The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer
- (2021) Mike Wenzel et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond
- (2021) Ting Martin Ma et al. RADIOTHERAPY AND ONCOLOGY
- Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies
- (2019) William C. Jackson et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
- (2019) Anders Widmark et al. LANCET
- Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
- (2019) Douglas H Brand et al. LANCET ONCOLOGY
- Multi-Center Trial of Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints
- (2018) Robert M. Meier et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer
- (2018) Shuichi Nishimura et al. Cancer Medicine
- Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer
- (2017) Charles N. Catton et al. JOURNAL OF CLINICAL ONCOLOGY
- Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
- (2017) Shaan Kataria et al. Frontiers in Oncology
- Stereotactic body radiation therapy for low and intermediate risk prostate cancer—Results from a multi-institutional clinical trial
- (2016) Raquibul Hannan et al. EUROPEAN JOURNAL OF CANCER
- Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
- (2016) W. Robert Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
- (2016) David Dearnaley et al. LANCET ONCOLOGY
- Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up
- (2016) D E Spratt et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Time to Nadir PSA
- (2015) Skyler B. Johnson et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience
- (2013) Leonard N Chen et al. Radiation Oncology
- Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years
- (2013) Alan J Katz et al. Radiation Oncology
- Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
- (2013) Christopher R. King et al. RADIOTHERAPY AND ONCOLOGY
- PSA Nadir of
- (2011) Eric C. Ko et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started